Post-menopausal bleeding is any vaginal bleeding occurring 12 or more months after the last menstrual period, requiring investigation to exclude endometrial carcinoma.

Post-Menopausal Bleeding (PMB)

3. Risk Factors

Understanding risk factors for PMB requires understanding what drives the most dangerous cause (endometrial cancer) and the most common cause (atrophic changes).

These all relate to unopposed oestrogen exposure — oestrogen stimulating the endometrium without the counterbalancing effect of progesterone.

Category	Risk Factor	Mechanism	Relative Risk
Exogenous oestrogens	Unopposed oestrogen therapy	Direct oestrogen stimulation of endometrium without progesterone opposition	2–10× ^[2]
	Tamoxifen in post-menopausal women	Tamoxifen is a SERM — antagonist in breast but partial agonist in endometrium → stimulates endometrial proliferation	2× ^[2]
	Phytoestrogens (herbal supplements)	Plant-derived compounds with weak oestrogenic activity; risk of supplementation on CA endometrium is controversial ^[2]	Uncertain
Endogenous oestrogens	Chronic WHO Type 2 anovulation (e.g., PCOS)	No ovulation → no corpus luteum → no progesterone → unopposed oestrogen ^[2]	3×
	Obesity	Adipose tissue contains aromatase → converts adrenal androgens (androstenedione) to oestrone (E1) → peripheral oestrogen production	2–5×
	Early menarche / Late menopause	Longer lifetime oestrogen exposure	Modest ↑
	Nulliparity	Fewer periods of progesterone dominance (pregnancy is a progesterone-dominant state)	2×
	Oestrogen-secreting ovarian tumours (e.g., granulosa cell tumour)	Direct oestrogen secretion from tumour	Variable
Metabolic	Diabetes mellitus	Hyperinsulinaemia → ↓SHBG → ↑free oestrogen; also direct mitogenic effect of insulin on endometrium	2×
	Metabolic syndrome / Hypertension	Often co-exists with obesity and DM; shared insulin resistance pathway	Associated
Genetic	Family history of CA breast/colon/endometrium	Lynch syndrome (HNPCC) — mismatch repair gene mutations → lifetime risk of endometrial cancer ~40–60%	Significant
Medications	Tamoxifen (reiterated due to importance)	As above	2× ^[2]
	Combined oestrogen-progestin HRT	Risk is NOT increased in combined preparations ^[2] — the progesterone component protects the endometrium	No increased risk

Key Concept: Unopposed Oestrogen

The unifying theme is unopposed oestrogen. Oestrogen drives endometrial proliferation. Without progesterone to induce secretory transformation and orderly shedding, the endometrium undergoes disordered proliferation → hyperplasia → atypia → carcinoma (the "hyperplasia-carcinoma sequence"). This is why combined HRT (oestrogen + progestin) does NOT increase risk, while oestrogen-only HRT does.

4. Anatomy and Function (Relevant to PMB)

The endometrium is the inner mucosal lining of the uterus, composed of two layers:

Functional layer (stratum functionalis): The superficial layer that proliferates, secretes, and sheds cyclically under hormonal influence. This is the layer that bleeds during menstruation — and the layer that becomes atrophic or hyperplastic in PMB.
Basal layer (stratum basalis): The deep layer that remains after shedding and regenerates the functional layer. It is relatively hormone-independent.

Hormonal Regulation of the Endometrium

Hypothalamus → GnRH → Anterior Pituitary → FSH + LH → Ovary → Oestrogen + Progesterone → Endometrium

Oestrogen (mainly E2 — oestradiol): Drives proliferation of endometrial glands and stroma (proliferative phase). Increases endometrial thickness, vascularity, and glandular development.
Progesterone: Produced by the corpus luteum after ovulation. Converts the proliferative endometrium into a secretory endometrium — glands become tortuous and secrete glycogen-rich fluid. Progesterone opposes oestrogen's proliferative effect and induces orderly differentiation.
After menopause: Ovarian follicles are depleted → minimal oestrogen and no progesterone → endometrium becomes thin and atrophic (normally ≤ 4 mm on transvaginal ultrasound).

5. Aetiology and Pathophysiology

The differential diagnoses for PMB ^[1]:

Cause	Approximate Frequency	Key Points
Atrophic vaginitis / endometritis	Most common	Due to post-menopausal hypoestrogenic state
Malignancy	~10%	From endometrium (commonest), uterine sarcoma, cervix, vagina, or vulva
Endometrial hyperplasia	Variable	Precursor to endometrial carcinoma
Endometrial polyps	Variable	May occur in perimenopausal or early post-menopausal women
Oestrogen exposure	Variable	From herbal supplements, hormonal treatment, endogenous tumours
Cervical pathology	Variable	Cervical polyps, cervicitis, cervical cancer
Vaginal/vulval pathology	Less common	Vaginal cancer, vulval cancer, trauma
Exogenous hormones (HRT)	Common if on HRT	Breakthrough bleeding, incorrect regimen

5.2 Detailed Pathophysiology of Each Cause

Pathophysiology — Two pathogenic types:

Feature	Type I (Endometrioid)	Type II (Non-endometrioid)
Frequency	~80%	~20%
Precursor	Atypical endometrial hyperplasia	Endometrial intraepithelial carcinoma (EIC)
Oestrogen-dependent?	Yes — arises from unopposed oestrogen	No — arises from atrophic endometrium
Patient profile	Younger, obese, perimenopausal	Older, thin, post-menopausal
Histology	Endometrioid adenocarcinoma	Serous papillary, clear cell
Grade	Usually low grade (well-differentiated)	Usually high grade
Prognosis	Better	Worse
Molecular	PTEN loss, MSI, KRAS, CTNNB1 mutations	TP53 mutations, HER2 amplification

The hyperplasia-carcinoma sequence for Type I:

Normal endometrium → Simple hyperplasia (1% → cancer) → Complex hyperplasia (3%) → Atypical hyperplasia (29%) → Endometrial carcinoma

Why does unopposed oestrogen cause cancer?

Oestrogen activates oestrogen receptors (ERα) in endometrial cells → ↑ cell proliferation.
More cell divisions → more chance of DNA replication errors → accumulation of mutations.
Without progesterone to induce differentiation and apoptosis, these proliferating cells have no "brakes".
Sequential accumulation of genetic hits (PTEN inactivation, microsatellite instability, etc.) drives the progression from hyperplasia to carcinoma.

7. Clinical Features

Symptom	Description	Pathophysiological Basis
Vaginal bleeding	Any bleeding after > 1 year of amenorrhoea; may range from spotting to heavy bleeding	Atrophic: fragile, thin endometrium/vaginal epithelium with dilated superficial vessels → rupture. Malignancy: tumour neovascularisation with abnormal, friable vessels → erosion and bleeding. Polyps: surface erosion of vascular polyp.
Vaginal dryness	Sensation of dryness, discomfort	Hypoestrogenic state → thinning of vaginal epithelium → ↓ glycogen → ↓ Lactobacillus → ↓ transudate production ^[1]
Vaginal irritation	Itching, burning, soreness	Atrophic epithelium is more susceptible to mechanical irritation and infection due to loss of protective acid pH and epithelial barrier
Vaginal discharge	May be watery, blood-stained, or purulent	Atrophic vaginitis: thin watery or blood-tinged discharge. Endometrial cancer: watery or blood-stained discharge (especially serous papillary type). Infection: purulent discharge secondary to altered vaginal flora
Dysuria	Pain on micturition	Atrophic bladder epithelium ^[1] — the urethral and bladder trigone epithelium is also oestrogen-dependent → atrophy → hypersensitivity to urine
Urgency, frequency, urge incontinence	Lower urinary tract symptoms	Atrophic bladder epithelium → loss of mucosal barrier → detrusor overactivity ^[1]
Dyspareunia	Pain during intercourse	Atrophic vagina: ↓ elasticity, ↓ lubrication, thinning → friction-related pain and microtrauma
Pelvic pain/pressure	Dull ache, heaviness	Uterine mass (sarcoma, advanced endometrial cancer, large polyp, fibroid) → mechanical pressure on surrounding structures
Weight loss, malaise	Constitutional symptoms	Advanced malignancy → catabolic state, cytokine release (TNF-α, IL-6)
Abdominal distension	Bloating, increasing girth	Ascites from advanced malignancy (peritoneal carcinomatosis), large ovarian mass (granulosa cell tumour producing oestrogen)

7.2 Signs

Physical examination approach for PMB ^[1]:

Sign	What to Look For	Pathophysiological Basis
BMI	Obesity (BMI ≥ 30)	Adipose tissue aromatase → peripheral conversion of androgens to oestrone → unopposed oestrogen → endometrial stimulation
Pallor	Conjunctival or palmar pallor	Chronic or heavy bleeding → iron deficiency anaemia → ↓ haemoglobin → pale mucous membranes
Cervical and groin lymph nodes	Lymphadenopathy	Metastatic spread from cervical, endometrial, vaginal, or vulval malignancy via lymphatic drainage (cervical → pelvic → para-aortic nodes; vulval → inguinal nodes)
Abdominal masses / ascites	Palpable mass, shifting dullness, fluid thrill	Advanced pelvic malignancy with peritoneal dissemination; oestrogen-producing ovarian tumour (granulosa cell tumour)

Sign	What to Look For	Pathophysiological Basis
Atrophic changes	Pale, dry, smooth, and shiny vaginal epithelium with petechial haemorrhage and patchy erythema, loss of rugae ^[1]	Oestrogen deprivation → thinning of stratified squamous epithelium → visible subepithelial capillaries → petechial haemorrhage from fragile vessels
Cervical lesion	Visible tumour, ulceration, contact bleeding	Cervical malignancy — disorganised neovascularisation and tumour necrosis
Cervical polyp	Smooth, red/pink pedunculated mass protruding from the os	Benign overgrowth of endocervical epithelium; bleeds on contact due to rich vascular supply
Blood at the os	Fresh blood coming from the cervical os	Suggests an endometrial or endocervical source (atrophy, polyp, cancer, hyperplasia)
Vaginal/vulval lesion	Ulcer, mass, discolouration	Vaginal or vulval malignancy, lichen sclerosus (white, thin, wrinkled skin → secondary fissuring and bleeding)

Sign	What to Look For	Pathophysiological Basis
Pelvic masses	Enlarged uterus, adnexal mass	Enlarged uterus: endometrial cancer expanding uterine cavity, uterine sarcoma, fibroids. Adnexal mass: ovarian tumour (granulosa cell tumour → oestrogen production → endometrial stimulation)
Uterine tenderness	Pain on palpation	Endometritis (infected atrophic endometrium), pyometra (pus in uterine cavity — cervical stenosis in elderly → drainage obstruction)
Fixed/immobile uterus	Restricted mobility	Advanced malignancy with parametrial invasion or pelvic sidewall fixation
Cervical motion tenderness	Pain on moving the cervix	Pelvic inflammatory disease (less common post-menopause), advanced malignancy

7.3 Signs Specific to Particular Aetiologies

8. Long-Term Sequelae of the Post-Menopausal State (Context for PMB)

Understanding PMB requires understanding the broader post-menopausal state:

9. Evaluation (History and Physical Examination Approach)

The approach to PMB evaluation ^[1]:

Domain	Key Questions	Rationale
Nature of bleeding	Onset, duration, amount, frequency, colour, presence of clots; any associating symptoms	Characterise severity; determine if cyclical (suggesting exogenous hormone use) or irregular
Association with previous menses	Is it the same as in previous menses?	Helps distinguish true PMB from perimenopausal bleeding in women who may not yet be truly post-menopausal
Drug use	TCM, hormonal replacement, tamoxifen	Exogenous oestrogen sources; tamoxifen-associated endometrial pathology
Health supplements / Food changes	Any that may contain exogenous oestrogen	Phytoestrogens in supplements widely used in Hong Kong
Risk factors for CA endometrium	Obesity, DM, previous anovulation, family history of CA breast/colon/endometrium, previous tamoxifen	Assess pre-test probability of endometrial malignancy
Previous cervical screening	Last Pap smear/HPV test, any abnormal results	Cervical cancer risk assessment
Menopausal symptoms	Hot flushes, night sweats, mood changes	Confirms menopausal status; if absent and on "HRT", consider whether diagnosis of menopause is correct
Sexual history	Dyspareunia, post-coital bleeding, recent intercourse	May reveal trauma to atrophic tissue or cervical pathology
Other bleeding symptoms	Haematuria, rectal bleeding	Exclude non-gynaecological source

As outlined above ^[1]:

General: BMI, pallor, cervical and groin lymph nodes, abdomen for masses/ascites
Speculum: neoplasm, atrophic changes
Bimanual exam: pelvic masses

High Yield Summary

Definition: Any uterine bleeding > 1 year after last natural menstrual period

Epidemiology: 4–11% of post-menopausal women; 10% are due to malignancy

Most Common Cause: Atrophic vaginitis/endometritis (hypoestrogenic)

Most Important Cause to Exclude: Endometrial cancer (most common malignancy causing PMB)

Risk Factors for Endometrial Cancer: All relate to unopposed oestrogen — obesity, DM, anovulation (PCOS), unopposed oestrogen HRT (2–10×), tamoxifen (2×), nulliparity, late menopause, Lynch syndrome

Key Principle: Combined oestrogen-progestin HRT does NOT increase risk (progesterone protects the endometrium)

Tamoxifen: Partial agonist in endometrium → can cause hyperplasia, polyps, carcinoma. No routine screening in asymptomatic patients. If symptomatic → EA + diagnostic hysteroscopy within 2 weeks

Atrophic Vaginitis Appearance: Pale, dry, smooth, shiny epithelium with petechial haemorrhage, patchy erythema, loss of rugae

History Must Include: Nature of bleeding, drug use (TCM, HRT, tamoxifen), supplements, risk factors for endometrial cancer

Examination Must Include: BMI, pallor, lymph nodes, abdomen (masses/ascites), speculum (neoplasm, atrophy), bimanual (pelvic masses)

Investigations (mandatory): Endometrial aspirate in ALL PMB cases; cervical cytology if no regular screening; TVUS (endometrial thickness ≤ 4 mm in post-menopausal = reassuring, NPV 99.4–100%); hysteroscopy ± biopsy if on tamoxifen, ET > 4 mm, or recurrent/refractory symptoms

Active Recall - Post-Menopausal Bleeding (PMB): Definition, Epidemiology, Aetiology, and Clinical Features

Differential Diagnosis of Post-Menopausal Bleeding (PMB)

The approach to differential diagnosis in PMB is fundamentally about localising the source and then identifying the pathology. Think anatomically — bleeding can come from the vulva, vagina, cervix, or uterus (endometrium) — and work systematically. But the overriding clinical imperative is always: PMB is a worrisome symptom → must rule out CA endometrium ^[1].

The following frequencies come from a combination of lecture material and large cohort data ^[1]^[3]:

Rank	Diagnosis	Approximate Frequency	Pathophysiological Category
1	Endometrial/cervical polyps	~37.7% ^[3]	Oestrogen-driven focal overgrowth
2	Atrophic vaginitis / atrophic endometritis	~30.8% ^[3] / commonest ^[1]	Hypoestrogenic
3	Proliferative/secretory endometrium	~14.5% ^[3]	Exogenous or endogenous oestrogen exposure
4	Malignancy	~6.6–10% ^[1]^[3]	Oestrogen-driven (Type I) or independent (Type II)
5	Fibroids (leiomyoma)	~6.2% ^[3]	Oestrogen/progesterone-responsive benign tumour
6	Endometrial hyperplasia	Variable	Unopposed oestrogen → precursor to Type I cancer
7	Oestrogen exposure	Variable	Herbal supplements, hormonal treatment, endogenous tumours ^[1]
8	Other (cervicitis, trauma, non-gynae)	Uncommon	Various

Frequency Discrepancy

Note that the lecture slides state atrophic vaginitis/endometritis is the commonest cause ^[1], while the UpToDate data from the theme case ranks polyps as most common (37.7%) and atrophy second (30.8%) ^[3]. Both are correct in different contexts — atrophic changes are the most common cause of symptomatic bleeding in many series, while polyps dominate in series where hysteroscopy is performed systematically (many polyps are found incidentally). For exams, know both — state atrophic vaginitis is the commonest clinical cause and polyps are the commonest hysteroscopic finding.

Detailed Differential Diagnoses

Oestrogen exposure from herbal supplements, hormonal treatment, or endogenous tumours ^[1].

Source	Mechanism	Key Point
Exogenous HRT (oestrogen-only)	Direct oestrogen stimulation of endometrium	Unopposed oestrogen HRT increases risk 2–10×; combined HRT does NOT
Tamoxifen	Partial agonist at endometrial oestrogen receptors	Causes polyps, hyperplasia, carcinoma; 2× risk in post-menopausal women
TCM / Herbal supplements	May contain undeclared oestrogens or phytoestrogens	Very common in Hong Kong — always ask specifically
Oestrogen-secreting ovarian tumours	Granulosa cell tumour, thecoma → direct oestrogen production	Suspect if adnexal mass + thickened endometrium

The theme case provides a useful framework for matching investigations to diagnoses ^[3]:

	Atrophic Vaginitis	Endometrial Cancer	Cervical Cancer
Naked eye appearance	Petechiae on pale, dry vaginal epithelium	Normal cervix (blood at os) OR bulky uterus	Exophytic or endophytic growth on cervix
Cervical smear	Yes (to exclude concurrent cervical pathology)	Yes (screening)	Not needed — should go straight for biopsy ^[3]
Cervical biopsy	Not needed	Not needed	Yes — must see architecture, depth of invasion ^[3]
Pelvic ultrasonography	May show thin endometrium (≤ 4 mm)	May show thickened endometrium (> 4 mm), uterine mass	May show cervical mass, hydronephrosis (advanced)
Hysteroscopy / endometrial biopsy	Not first line (if atrophy confirmed and no other concerns)	Yes — mandatory endometrial aspirate in all cases of PMB ^[1]	Not for primary diagnosis
Diagnostic certainty	Diagnosis of exclusion ^[3]	Histological diagnosis from endometrial sampling	Histological diagnosis from cervical biopsy

Critical Exam Point

If you see a visible cervical lesion on speculum, do NOT rely on a cervical smear — go straight for cervical biopsy ^[3]. A Pap smear samples only superficial cells and can miss invasive cancer (false negative). Biopsy provides tissue architecture, which is essential for diagnosing invasion depth and tumour type. This is a commonly tested point.

Feature	Atrophic Changes	Endometrial Polyp	Endometrial Cancer	Cervical Cancer
Bleeding pattern	Light spotting, often after trauma/coitus	Irregular spotting, may be cyclical if oestrogen-sensitive	Persistent, may be heavy, often spontaneous	Post-coital, contact bleeding
Discharge	Thin, watery	Minimal	Watery, blood-stained, offensive (if necrotic)	Offensive, blood-stained
Pain	Dyspareunia	Usually painless	Usually painless early; pain suggests advanced disease	Pelvic pain suggests parametrial invasion
Speculum	Pale, dry, petechiae, loss of rugae	May see polyp at os	Blood at os, usually normal cervix	Visible lesion — exophytic or endophytic
Bimanual	Normal or small atrophic uterus	Normal	Enlarged, irregular uterus (advanced)	Cervix may be hard, barrel-shaped; parametrial thickening
TVUS endometrial thickness	≤ 4 mm	Focal thickening, vascular pedicle on Doppler	> 4 mm (diffuse thickening)	May be normal or show cervical mass
Risk factor profile	All post-menopausal women (universal)	Tamoxifen, HRT	Obesity, DM, anovulation, tamoxifen, Lynch syndrome	HPV, no screening, smoking, immunosuppression

The clinical approach can be summarised in a stepwise fashion:

Step 1: Confirm PMB — Is this truly post-menopausal bleeding? (Amenorrhoea > 12 months? Not perimenopausal bleeding?)

Step 2: Localise the source — Speculum examination.

Vulval/vaginal lesion → biopsy
Cervical lesion → cervical biopsy directly (do NOT just do smear) ^[3]
Blood from the cervical os with normal-looking cervix → endometrial source → proceed to Step 3

Step 3: Assess the endometrium — Endometrial aspirate is mandatory in ALL cases of PMB ^[1]

TVUS for endometrial thickness: should be ≤ 4 mm in post-menopausal women (NPV 99.4–100%) ^[1]
If ET ≤ 4 mm and benign aspirate → likely atrophic changes
If ET > 4 mm, on tamoxifen, or recurrent/refractory symptoms → hysteroscopy ± endometrial biopsy ^[1]

Step 4: Exclude non-gynaecological sources — Urinalysis (haematuria?), rectal examination if indicated.

High Yield Summary

Differential Diagnosis of PMB — ranked by frequency:

Polyps (~37.7%) or Atrophic vaginitis/endometritis (commonest clinical cause, ~30.8%)
Proliferative/secretory endometrium (~14.5%)
Malignancy (~6.6–10%) — endometrium is the commonest malignant cause; cervical, vaginal, and vulval cancer also possible
Fibroids (~6.2%)
Endometrial hyperplasia, oestrogen exposure, other

Two key principles:

PMB is a worrisome symptom → must rule out CA endometrium ^[1]
Atrophic vaginitis is a diagnosis of exclusion — always exclude malignancy first

Critical investigation points:

Endometrial aspirate: mandatory in ALL cases of PMB ^[1]
Visible cervical lesion → go straight for cervical biopsy, NOT just smear ^[3]
TVUS endometrial thickness ≤ 4 mm has NPV 99.4–100% ^[1]

Active Recall - Differential Diagnosis of PMB

References

^[1] Lecture slides: Adrian Lui Gynecology Notes.pdf (p22) ^[3] Lecture slides: Block C - O&G Theme Case 2.docx.pdf (p6)

Diagnostic Criteria, Algorithm, and Investigation Modalities for Post-Menopausal Bleeding (PMB)

1. Diagnostic Criteria

PMB is itself a clinical symptom, not a disease — so there is no "diagnostic criteria" for PMB per se. The diagnostic question is: what is causing the PMB? The systematic investigation aims to:

Confirm the diagnosis of menopause (was this truly post-menopausal?)
Localise the source of bleeding (vulva, vagina, cervix, endometrium, non-gynaecological)
Obtain histological diagnosis to rule out malignancy

Parameter	Cut-off	Significance
Endometrial thickness on TVUS	≤ 4 mm in post-menopausal women	NPV 99.4–100% for excluding endometrial cancer ^[1]
Endometrial thickness on TVUS	> 4 mm	Requires further investigation (hysteroscopy ± biopsy)
Incidental thickened endometrium (asymptomatic)	> 11 mm AND a/w other US findings or RFs	Only then is endometrial aspirate indicated ^[1]
Endometrial thickness with tamoxifen	Unreliable	TVUS screening is not ideal because tamoxifen may lead to false-positive endometrial thickness due to myometrial vacuolation ^[2]

The 4 mm Rule — Understanding from First Principles

Why 4 mm? After menopause, the endometrium should be thin and atrophic because there is no oestrogen to drive proliferation. A normal post-menopausal endometrium measures ≤ 4 mm (bilayer thickness on TVUS). An endometrium thicker than 4 mm suggests either:

Oestrogen stimulation (exogenous or endogenous)
An endometrial lesion (polyp, hyperplasia, cancer)

At 4 mm: sensitivity 96%, specificity 53% ^[4]. At 5 mm: sensitivity 96%, specificity 61% ^[4]. The high sensitivity means a thin endometrium effectively rules out cancer. The modest specificity means many women with ET > 4 mm will have benign pathology — but you cannot afford to miss the malignancies, so you investigate all of them.

Asymptomatic Thickened Endometrium — Common Exam Trap

Endometrial aspirate is NOT routinely performed in asymptomatic patients with incidental finding of thickened endometrium unless > 11 mm and associated with other ultrasound findings or risk factors ^[1]. This is frequently tested. The rationale: in asymptomatic women, the pre-test probability of cancer is low, and the 4 mm threshold was validated in symptomatic (PMB) women. In asymptomatic women, the false-positive rate is high, leading to unnecessary invasive procedures.

2. Diagnostic Algorithm

The algorithm follows a logical, stepwise approach: History → Examination → First-line investigations → Second-line investigations based on findings.

3. Investigation Modalities — Detailed

Indicated if no regular screening ^[1].

What it is: A sample of exfoliated cells from the cervical transformation zone, smeared on a slide or placed in liquid medium, then examined microscopically.

Purpose in PMB: To screen for cervical pre-cancer or cancer. Also, occasionally picks up abnormal glandular cells that may suggest endometrial pathology.

Key findings and interpretation:

Finding	Interpretation	Action
Normal / NILM	No cervical abnormality	Does NOT exclude endometrial pathology — proceed with EA + TVUS
ASCUS / LSIL / HSIL	Cervical squamous abnormality	Colposcopy pathway (separate from PMB workup)
AGC-endometrial	Abnormal glandular cells of endometrial origin	First-line: endometrial aspirate ^[4]
Other AGC	Abnormal glandular cells (origin uncertain)	Colposcopy AND endometrial aspirate ^[4]
Benign endometrial cells	Normally shed endometrial cells found on smear	If ≥ 45 years + symptomatic or post-menopausal → endometrial aspirate ^[4]

Important Principle

A normal cervical smear does NOT exclude cervical cancer if a visible lesion is present. Smear is a screening test for pre-invasive disease. If you see a lesion, biopsy it directly ^[3]. Similarly, a normal smear says nothing about the endometrium — you still need endometrial sampling.

Mandatory in ALL cases of PMB ^[1].

What it is: A thin, flexible plastic catheter (Pipelle de Cornier is the most common device) is inserted through the cervix into the uterine cavity. Suction is applied by withdrawing the internal plunger, aspirating a strip of endometrial tissue.

"Endometrial aspirate" → "endo" = within, "metrial" = uterine wall; "aspirate" = sucked out. You are literally sucking out a strip of the inner lining of the womb.

Why is it first-line?

Simple office-based procedure that can provide histopathology ^[4]
Very commonly done and can be completed in 5 minutes without anaesthesia ^[4]
Sensitivity for endometrial cancer: ~90–99% (high — but not 100%)
Can be done in the outpatient clinic, no sedation needed
Provides histological tissue — the gold standard for diagnosis

Limitations:

Blind procedure: Samples only a strip of endometrium — may miss focal lesions (polyps, small cancers). This is why hysteroscopy is added when clinical suspicion is high.
Inadequate sample: May occur if the endometrium is very atrophic (too thin to sample), if there is cervical stenosis (common in elderly), or if the uterine cavity is distorted.
Cannot assess architecture: Unlike hysteroscopy, you cannot see the cavity directly.

Indications beyond PMB ^[4]:

AUB: persistent intermenstrual/irregular bleeding if age ≥ 40, any AUB if age ≥ 45, or otherwise indicated (obesity, PCOS, tamoxifen, failed treatment)
Abnormal Pap smear: AGC-endometrial (1st line), other AGC (together with colposcopy), benign endometrial cells (if ≥ 45 + symptomatic or post-menopausal)
Monitoring in previous endometrial pathology or surveillance in high-risk (e.g., HNPCC/Lynch syndrome)

Key histological findings and interpretation:

Histological Finding	Interpretation	Next Step
Atrophic / inactive endometrium	Consistent with post-menopausal atrophy — benign	Treat atrophic vaginitis if symptomatic; reassure
Proliferative endometrium	Unexpected in post-menopausal women — suggests oestrogen exposure	Investigate source of oestrogen (HRT, supplements, ovarian tumour)
Secretory endometrium	Suggests progesterone exposure — unusual post-menopause unless on HRT	Review medications
Endometrial polyp (fragments)	Benign polyp — but may be missed or incompletely sampled	Hysteroscopy for definitive diagnosis and polypectomy
Hyperplasia without atypia	Low risk of progression (~1–3%)	Progestin therapy + follow-up EA in 3–6 months
Atypical hyperplasia	High risk — ~29% progress to cancer; ~40% have concurrent carcinoma	Consider hysteroscopy + hysterectomy
Endometrial adenocarcinoma	Malignant — definitive diagnosis	Staging investigations + surgical management
Insufficient / inadequate sample	Not diagnostic — cannot exclude pathology	Consider repeat EA, hysteroscopy, or D&C under anaesthesia

TVUS for endometrial thickness: should be ≤ 4 mm in post-menopausal women (NPV 99.4–100%) ^[1].

What it is: A high-frequency (7.5–10 MHz) ultrasound probe inserted into the vagina to visualise the uterus, endometrium, and adnexae. The close proximity of the probe to the structures of interest provides superior resolution compared to transabdominal ultrasound.

Why transvaginal and not transabdominal? The vaginal probe is physically closer to the uterus and ovaries → higher frequency probe can be used → better resolution of the endometrium. Transvaginal ultrasound is the imaging modality of choice for pelvic pathology in the context of PMB ^[6].

What to measure: Endometrial thickness (ET) — measured as the maximal anteroposterior bilayer thickness (both layers of the endometrium together) in the sagittal plane at the thickest point.

Key findings and interpretation:

TVUS Finding	Interpretation	Action
ET ≤ 4 mm, homogeneous, thin stripe	Normal post-menopausal atrophic endometrium. NPV 99.4–100% ^[1]	If EA also benign → very reassuring. Treat atrophy.
ET > 4 mm, diffusely thickened	Suggests endometrial pathology — hyperplasia, cancer, or generalised oestrogen effect	Hysteroscopy ± endometrial biopsy ^[1]
Focal thickening / intracavitary mass	Suggests endometrial polyp or submucosal fibroid	Hysteroscopy for direct visualisation, polypectomy/biopsy
Heterogeneous endometrium with irregular myometrial border	Suspicious for endometrial cancer with myometrial invasion	Urgent hysteroscopy + biopsy; consider MRI for staging
Fluid in endometrial cavity (hydrometra / haematometra)	Cervical stenosis with trapped secretions; must exclude endometrial cancer	Drain + endometrial sampling
Thickened endometrium on tamoxifen	May be false positive due to myometrial vacuolation ^[2] — tamoxifen causes cystic changes in the subendometrial myometrium that ultrasonically mimic endometrial thickening	Proceed to EA + diagnostic hysteroscopy regardless ^[2]
Adnexal mass	Consider oestrogen-secreting ovarian tumour (granulosa cell tumour) as cause of endometrial stimulation	CT/MRI pelvis, tumour markers (inhibin, oestradiol)
Post-menopausal ovarian cyst with solid components and vascularity	Likely malignant in post-menopausal context ^[6]	CA-125, CT staging, MDT referral

Performance characteristics ^[4]:

ET Cut-off	Sensitivity	Specificity
4 mm	96%	53%
5 mm	96%	61%

Why is specificity low? Many benign conditions (polyps, simple hyperplasia, HRT effect) cause ET > 4 mm. The threshold is deliberately set low to maximise sensitivity (you don't want to miss cancer), accepting more false positives that will be sorted out by histology.

Indicated if: on tamoxifen, endometrial thickness > 4 mm, recurrent/refractory symptoms despite given treatment for atrophic changes ^[1].

What it is: "Hystero" = womb (Greek hystera), "scopy" = looking at. A thin telescope is inserted through the cervix into the uterine cavity, which is distended with saline or CO₂ gas, allowing direct visualisation of the endometrial surface.

Why is it superior to blind EA?

Direct visualisation: Can see the entire endometrial cavity, identify focal lesions (polyps, small cancers) that a blind EA might miss.
Directed biopsy: Can take biopsies from specific suspicious areas rather than random sampling.
Therapeutic capability: Can perform polypectomy, remove submucosal fibroids, and resect focal lesions at the same sitting.

Types:

Diagnostic hysteroscopy (DH): Visualisation + biopsy. Can be done in outpatient setting (office hysteroscopy) with miniature scopes (< 5 mm).
Operative hysteroscopy: Under general anaesthesia. For polypectomy, myomectomy, endometrial resection.

Key hysteroscopic findings and interpretation:

Finding	Appearance	Significance
Normal atrophic endometrium	Thin, pale, smooth, vascular pattern visible	Benign — consistent with post-menopausal atrophy
Endometrial polyp	Smooth, rounded, pedunculated mass on a stalk, often with a visible feeding vessel	Usually benign — excise and send for histology (0.5–3% harbour malignancy)
Submucosal fibroid	Round, firm, white mass bulging into cavity, covered by normal endometrium	Benign — may cause bleeding by distorting vasculature and increasing endometrial surface area
Endometrial hyperplasia	Thickened, polypoid, irregular endometrium, often with abnormal vascular patterns	Take directed biopsies — classification (with/without atypia) determines management
Suspicious for cancer	Irregular, friable, necrotic tissue, atypical vessels (corkscrew, interrupted), focal or diffuse	Multiple directed biopsies — histology confirms diagnosis and grade
Synechiae (adhesions)	Thin or thick bands traversing the cavity	Asherman's syndrome — may cause haematometra but uncommon cause of PMB

Complications of hysteroscopy (important to know for consent):

Uterine perforation (~0.1–1%)
Infection
Bleeding
Fluid overload (if using fluid distension medium)
False passage creation

Investigation	When Indicated	What It Tells You
Full blood count	All cases of PMB	Haemoglobin — assess for anaemia from chronic/heavy bleeding
Coagulation screen	If heavy bleeding or suspected coagulopathy	Exclude bleeding diathesis
Cervical biopsy	Visible cervical lesion → biopsy directly ^[3]	Histological diagnosis of cervical cancer — must see architecture and depth of invasion
MRI pelvis	Confirmed endometrial cancer → pre-operative staging	Depth of myometrial invasion, cervical stromal invasion, lymph node involvement. Superior soft tissue contrast compared to CT.
CT chest/abdomen/pelvis	Staging for confirmed malignancy	Distant metastases (lungs, liver, peritoneum, lymph nodes)
CA-125	Suspected ovarian pathology or advanced endometrial cancer	Elevated in ovarian cancer, advanced endometrial cancer, peritoneal disease. Not diagnostic alone.
Inhibin A/B, oestradiol	Suspected granulosa cell tumour	Elevated inhibin = granulosa cell tumour marker; elevated oestradiol = oestrogen-producing tumour
Baseline investigations for HRT initiation	If initiating HRT	BP/pulse, urinalysis, lipid profile, LFT, bone biochemistry, TSH, mammography ^[5]

Clinical Scenario	First-Line Investigation	Second-Line Investigation
PMB, no visible lesion	EA (mandatory) + TVUS ^[1]	Hysteroscopy if ET > 4 mm, inadequate EA, or refractory symptoms
PMB, visible cervical lesion	Cervical biopsy directly ^[3]	Staging CT/MRI if cancer confirmed
PMB on tamoxifen	EA + diagnostic hysteroscopy ^[2]	Do not rely on TVUS for ET
Asymptomatic thickened ET	NOT routinely investigated unless > 11 mm + other US findings/RFs ^[1]	If indicated → EA
PMB with adnexal mass	TVUS + EA	CT/MRI, tumour markers (CA-125, inhibin)
PMB with bulky uterus	EA + TVUS	MRI if cancer suspected (myometrial invasion assessment)
HRT user with new bleeding	Assess timing relative to regimen	Endometrial biopsy if: bleeding not at time of progestin withdrawal (cyclical), or bleeding after achieved amenorrhoea (continuous combined) ^[5]

The power of the PMB workup lies in combining TVUS, EA, and hysteroscopy results:

ET on TVUS	EA Result	Clinical Interpretation	Next Step
≤ 4 mm	Atrophic/benign	Very high confidence that this is atrophic change (NPV ~100%)	Treat with local oestrogen; reassure
≤ 4 mm	Inadequate sample	Thin endometrium makes cancer very unlikely, but sample is not diagnostic	Clinical follow-up; repeat EA or hysteroscopy if symptoms persist
> 4 mm	Atrophic/benign	Discordant — thick endometrium but benign histology. May have a focal lesion (polyp) missed by blind EA	Hysteroscopy to visualise cavity directly
> 4 mm	Hyperplasia (no atypia)	Consistent — oestrogen-driven proliferation	Progestin therapy + repeat EA in 3–6 months
> 4 mm	Atypical hyperplasia	High risk — possible concurrent carcinoma (~40%)	Hysteroscopy + consider hysterectomy
> 4 mm	Carcinoma	Definitive diagnosis	MRI pelvis staging → MDT → surgery
Any (tamoxifen)	Any	TVUS unreliable; EA + hysteroscopy are the definitive investigations	Manage based on histology

The 'Discordant' Result — Why Hysteroscopy Matters

The classic exam scenario: TVUS shows ET > 4 mm but EA returns "insufficient tissue" or "benign." Does this mean there's no cancer? No. The EA is a blind procedure — it samples only a strip of endometrium and can miss a focal polyp or small carcinoma. When the TVUS and EA results are discordant (thick endometrium but benign/inadequate EA), hysteroscopy is essential to directly visualise and biopsy focal lesions. This is why hysteroscopy is the final arbiter.

High Yield Summary

Key Investigation Principles in PMB:

Endometrial aspirate is MANDATORY in ALL cases of PMB ^[1] — simple, office-based, 5-minute procedure, no anaesthesia needed
TVUS endometrial thickness ≤ 4 mm = NPV 99.4–100% ^[1] — effectively rules out endometrial cancer
TVUS performance: at 4 mm, sensitivity 96%, specificity 53%; at 5 mm, sensitivity 96%, specificity 61% ^[4]
Hysteroscopy ± biopsy indicated if: on tamoxifen, ET > 4 mm, or recurrent/refractory symptoms ^[1]
Visible cervical lesion → cervical biopsy directly (NOT just smear) ^[3]
EA is NOT routinely done for asymptomatic thickened endometrium unless > 11 mm with other US findings or risk factors ^[1]
Tamoxifen causes false-positive ET thickening on TVUS (myometrial vacuolation) → proceed directly to EA + DH ^[2]
For HRT users with bleeding: no intervention needed in first 6 months; after that, timing of bleeding relative to progestin dictates need for biopsy ^[5]

Active Recall - PMB: Diagnostic Criteria, Algorithm, and Investigations

References

^[1] Lecture slides: Adrian Lui Gynecology Notes.pdf (p22) ^[2] Lecture slides: Adrian Lui Gynecology Notes.pdf (p96) ^[3] Lecture slides: Block C - O&G Theme Case 2.docx.pdf (p6) ^[4] Lecture slides: Adrian Lui Gynecology Notes.pdf (p97) ^[5] Lecture slides: Adrian Lui Gynecology Notes.pdf (p36) ^[6] Senior notes: Ryan Ho Radiology.pdf (p34, p40)

Management of Post-Menopausal Bleeding (PMB)

Detailed Management by Aetiology

Local oestrogen cream: for atrophic vaginitis/endometritis ^[1]

Regimen: Premarin cream 0.5g QD × 2 weeks then 3×/week for 6 months ^[1]

First principles — why does local oestrogen work?

The problem is oestrogen deficiency → thinned, fragile vaginal and endometrial epithelium.
Replacing oestrogen locally restores epithelial thickness, glycogen content, Lactobacillus colonisation, vaginal pH, and vascularity.
"Premarin" = Pregnant mares' urine — conjugated equine oestrogens. The cream delivers oestrogen directly to the vaginal epithelium.

Why local rather than systemic?

Local (topical vaginal) oestrogen delivers therapeutic concentrations to the vagina with minimal systemic absorption → avoids the risks of systemic HRT (VTE, breast cancer, endometrial stimulation).
Systemic oestrogen is reserved for women with significant vasomotor symptoms or other indications for HRT.

Available local oestrogen preparations:

Preparation	Active Ingredient	Regimen	Notes
Premarin cream	Conjugated equine oestrogens	0.5g QD × 2 weeks, then 3×/week for 6 months ^[1]	Most commonly mentioned in HK protocols
Ovestin cream	Oestriol (E3)	0.5 mg QD × 2–3 weeks, then 2×/week	E3 is weaker → even less systemic absorption
Vagifem tablet	Oestradiol (E2) 10 μg	1 tablet PV QD × 2 weeks, then 2×/week	More convenient; less messy than cream
Estring ring	Oestradiol	Inserted Q3 months	Continuous low-dose release; good compliance

Important points:

Local vaginal oestrogen at standard doses does NOT require concurrent progestogen even in women with an intact uterus — the systemic absorption is negligible.
Treatment duration: can be long-term/indefinite for symptomatic relief, as symptoms recur upon cessation.
If symptoms are refractory to topical oestrogen → hysteroscopy ± endometrial biopsy ^[1] to exclude a missed pathology.

Follow-Up After Treatment for Atrophy

Review OT record if hysteroscopy performed ^[1]. Review histopathology report for endometrial biopsy ^[1]. If treated empirically with oestrogen cream and symptoms resolve → routine follow-up. If symptoms persist or recur → must reassess and consider hysteroscopy.

3. Endometrial Hyperplasia

Management depends on the presence or absence of cytological atypia — this is the critical distinction:

Risk of progression to cancer: ~1–3%. This is a low-risk condition that is often reversible with progestin therapy.

First-line: Progestin therapy

Why progestins? Progesterone opposes oestrogen's proliferative effect on the endometrium. It induces:
1. Secretory differentiation of glandular epithelium
2. Stromal decidualisation
3. Apoptosis of endometrial cells
4. Down-regulation of oestrogen receptors → Net effect: reversal of the hyperplastic process.

Progestin options:

Regimen	Details	Notes
Mirena LNG-IUS	Levonorgestrel 20 μg/day intrauterine system	Preferred — delivers high local progestin concentration directly to endometrium with minimal systemic side effects. Regression rate ~90%. Also provides contraception if perimenopausal.
Oral medroxyprogesterone acetate (MPA)	10–20 mg/day for 12–14 days per month (cyclical) or continuous	Systemic side effects (bloating, mood changes, weight gain). Regression rate ~70–80%.
Oral norethisterone	10–15 mg/day cyclical or continuous	Similar efficacy and side effect profile to MPA

Follow-up: Repeat endometrial aspirate at 3–6 months to confirm regression.

If regression confirmed → continue surveillance (EA every 6–12 months for ≥ 2 samples after regression)
If no regression or progression → consider hysterectomy

Identify and address the underlying cause of unopposed oestrogen:

Obesity → weight loss counselling (↓ peripheral aromatase activity)
Exogenous oestrogen → add progestin or stop unopposed oestrogen
Anovulation → induce ovulation or provide progestin

This is the most feared diagnosis and requires a structured, multidisciplinary approach.

Staging: FIGO surgical staging (2009, updated 2023):

Stage	Description
IA	Tumour confined to endometrium or invades < 50% myometrium
IB	Tumour invades ≥ 50% myometrium
II	Tumour invades cervical stroma
IIIA	Tumour invades serosa and/or adnexae
IIIB	Vaginal and/or parametrial involvement
IIIC1	Pelvic lymph node metastasis
IIIC2	Para-aortic lymph node metastasis
IVA	Tumour invades bladder and/or bowel mucosa
IVB	Distant metastasis

Pre-operative workup for staging:

MRI pelvis (preferred): Depth of myometrial invasion, cervical stromal invasion, lymph node status
CT chest/abdomen/pelvis: Distant metastases
Blood tests: FBC, RFT, LFT, CA-125 (elevated in advanced disease)
CXR, ECG, pre-operative anaesthetic assessment

Surgical management (mainstay):

Component	Details	Rationale
Total abdominal hysterectomy (TAH)	Removal of the entire uterus including cervix	Removes the primary tumour
Bilateral salpingo-oophorectomy (BSO)	Removal of both ovaries and fallopian tubes	Removes potential oestrogen source; ovaries are common site of occult metastasis
Pelvic ± para-aortic lymph node dissection	Systematic sampling or complete dissection	Surgical staging; identifies nodal metastasis that determines adjuvant therapy
Peritoneal washings	Cytological examination of peritoneal fluid	Staging information (though removed from formal FIGO staging in 2009, still often performed)
Omentectomy	Removal of the greater omentum	Especially in serous/clear cell (Type II) histology — propensity for peritoneal spread

Minimally invasive surgery (laparoscopic or robotic-assisted): Increasingly used for early-stage disease. Equivalent oncological outcomes with less morbidity.

Sentinel lymph node mapping: Emerging technique to reduce morbidity of full lymph node dissection in early-stage disease.

Adjuvant therapy (based on stage, grade, histological type, and molecular classification):

Risk Category	Criteria	Adjuvant Therapy
Low risk	Stage IA, Grade 1–2, endometrioid, no LVSI	Observation only
Intermediate risk	Stage IA Grade 3, or Stage IB Grade 1–2	Vaginal cuff brachytherapy (VBT)
High-intermediate risk	Stage IB Grade 3, or LVSI+, or age > 60 with 2+ risk factors	Pelvic external beam RT (EBRT) ± VBT
High risk	Stage II–III, or Type II histology (serous, clear cell)	EBRT + chemotherapy (platinum-based, e.g., carboplatin + paclitaxel)
Advanced / Metastatic	Stage IVA/IVB	Systemic chemotherapy ± palliative RT

Hormonal therapy with tamoxifen is used for breast cancer but has endometrial side effects — SERM (e.g., tamoxifen): side effects include weight gain, flushing, ↑ risk of CA corpus, VTE ^[7].

Molecular classification (TCGA/ProMisE) — increasingly used to guide adjuvant therapy:

POLE ultramutated: Excellent prognosis → may de-escalate adjuvant therapy
MSI-high / dMMR: Good prognosis; immunotherapy (pembrolizumab) if advanced
Copy number low (p53 wildtype): Intermediate prognosis
Copy number high (p53 mutant): Poor prognosis → aggressive adjuvant therapy

Management is stage-dependent. This is briefly outlined here as PMB may be the presenting symptom:

Stage	Management
IA1 (microinvasive, no LVSI)	Cone biopsy (fertility-sparing) or simple hysterectomy
IA2–IB1	Radical hysterectomy + pelvic lymphadenectomy OR primary chemoradiation
IB2–IIA	Radical hysterectomy or primary chemoradiation (cisplatin-based)
IIB–IVA	Primary chemoradiation (cisplatin + EBRT + brachytherapy)
IVB	Palliative chemotherapy ± immunotherapy (pembrolizumab if PD-L1+)

Oestrogen exposure from herbal supplements, hormonal treatment, or endogenous tumours ^[1]

Management principle: Identify and remove the source.

Source	Action
TCM / Herbal supplements	Stop the offending product — counsel that these may contain undeclared oestrogens ^[1]
Unopposed oestrogen HRT	Add progestin if uterus intact — presence of uterus: cannot use unopposed oestrogen ^[5]
Tamoxifen	Cannot simply stop (needed for breast cancer); manage endometrial complications as they arise
Phytoestrogen supplements	Discuss risks; consider stopping

HRT adjustment if bleeding occurs on HRT ^[5]:

Choosing a suitable HRT regimen ^[5]:

Presence of uterus: cannot use unopposed oestrogen → must add progestin (combined regimen)
Time since menopause: > 2 years can use continuous regimen (aims for amenorrhoea)
< 2 years since menopause: use cyclical regimen (expected withdrawal bleed)

Management of bleeding on HRT ^[5]:

Breakthrough bleeding occurring in first 6 months of treatment requires no immediate intervention
For combined cyclical regimen: if bleeding is not around time of progestin withdrawal / persistently irregular → endometrial biopsy
For continuous combined regimen: if bleeding occurs after achievement of amenorrhoea → endometrial biopsy

Stopping HRT: no universal rule ^[5]:

Principle = lowest dose for shortest possible duration for symptom relief
Exception: premature ovarian insufficiency (POI) — continue until natural menopausal age (~50)

Contraindications to HRT (important to know — determines whether you can use it at all):

Absolute Contraindications	Relative Contraindications
Active or recent VTE	History of VTE (can consider transdermal route — bypasses first-pass hepatic effect → less prothrombotic)
Active or recent arterial thromboembolic disease (MI, stroke)	Strong family history of VTE
Known or suspected breast cancer	Uncontrolled hypertension
Known or suspected oestrogen-dependent malignancy	Active liver disease
Undiagnosed abnormal genital bleeding	Endometriosis (may reactivate)
Untreated endometrial hyperplasia	Gallbladder disease
Active liver disease / acute porphyria	Migraine with aura

Why Transdermal HRT is Safer for VTE Risk

Oral oestrogen undergoes first-pass metabolism in the liver → ↑ hepatic synthesis of clotting factors (factors VII, X, fibrinogen) and ↓ antithrombin III → prothrombotic state. Transdermal oestrogen (patches, gels) bypasses the liver → minimal effect on clotting factors → significantly lower VTE risk. This is why transdermal is preferred in women with VTE risk factors.

Side effects of HRT (usually transient) ^[5]:

Breast tenderness, fluid retention, GI upset, headache, irregular bleeding

Routine follow-up on HRT ^[5]:

2nd visit in 2–4 months, then subsequent F/U in 6–12 months
Every visit: body weight, BP, urinalysis
Routine PE: general, thyroid, cardiac, chest & abdominal exam, breast exam, pelvic exam
Routine investigations: cervical smear Q3 years, mammogram ± lipid profile, LFT, fasting glucose every 2 years; BMD studies if indicated

Although fibroids typically regress post-menopause, those that persist (or grow on HRT/tamoxifen) may cause PMB.

Surgical management of fibroids ^[8]:

Indications for surgery ^[8]:

Symptomatic — but warn patient that urinary frequency may not improve as it may be due to detrusor instability
Rapid growth or post-menopausal growth → worrisome of malignancy

Approach	Details	When to Use
Hysteroscopic resection	Resection of submucosal fibroid under hysteroscopic guidance ± endometrial ablation	Submucosal fibroids < 3–4 cm; preserves uterus
Hysterectomy	Indications: acute haemorrhage not responding to other therapies; completed childbearing; ↑ risk for CA cervix/endometrium/ovaries ^[8]	Definitive treatment; post-menopausal women who are symptomatic
Uterine artery embolisation (UAE)	Transcatheter embolisation of uterine arteries ^[9] — embolic agents block blood supply to fibroids → ischaemic necrosis → shrinkage	Alternative treatment ^[8]; generally for premenopausal women but can be used in select post-menopausal cases

Medical treatment of fibroids ^[8] — less relevant in the post-menopausal setting as most fibroids should be regressing, but includes:

Tranexamic acid: oral 1g TDS up to 4 days, max 4g daily — reduces fibrinolysis → ↓ bleeding
Iron supplement: oral ferrous sulphate 300mg TDS × 6 months if Hb < 10 g/dL
GnRH agonists/antagonists: pre-operative ↓ size before hysteroscopic resection
- MoA: desensitisation → medically induce menopause → ↓ size of fibroid — but NOT for long-term use due to significant climacteric symptoms and menopause-related side effects (e.g., bone density) ^[8]
- Rapid relapse following discontinuation ^[8]

Diagnosis	First-Line Treatment	Second-Line / If Refractory	Key Points
Atrophic vaginitis/endometritis	Local oestrogen cream (Premarin 0.5g QD × 2w then 3×/w for 6m) ^[1]	Hysteroscopy ± biopsy ^[1]	Most common cause; diagnosis of exclusion
Endometrial polyp	Hysteroscopic polypectomy + histology	—	Always send for histology (0.5–3% malignant)
Hyperplasia without atypia	Progestin therapy (Mirena preferred)	Hysterectomy if no regression	~1–3% progress to cancer; usually reversible
Atypical hyperplasia	Hysterectomy (TAH + BSO)	High-dose progestin if fertility desired	~29% progress; ~40% have concurrent cancer
Endometrial cancer	TAH + BSO ± LN dissection ± adjuvant	Chemo/RT based on stage	MDT approach; molecular classification emerging
Cervical cancer	Surgery (early) or chemoradiation (advanced)	Palliative chemo for stage IV	Stage-dependent; biopsy visible lesions directly
Exogenous oestrogen	Remove source; add progestin if on unopposed oestrogen	—	Cannot use unopposed oestrogen if uterus present ^[5]
Oestrogen-secreting tumour	Surgical excision (oophorectomy / TAH + BSO)	—	Follow inhibin B and oestradiol
Submucosal fibroid	Hysteroscopic resection	Hysterectomy ^[8]	Post-menopausal growth → worrisome of malignancy ^[8]

High Yield Summary

General Principle: Treatment is guided to the underlying cause ^[1]

Atrophic Vaginitis: Local oestrogen cream (Premarin 0.5g QD × 2 weeks then 3×/week for 6 months) ^[1] — first-line. If refractory → hysteroscopy to exclude missed pathology.

Endometrial Hyperplasia: Without atypia → progestin therapy (Mirena LNG-IUS preferred) + follow-up EA at 3–6 months. Atypical → hysterectomy (TAH + BSO), because ~29% progress and ~40% already harbour carcinoma.

Endometrial Cancer: Surgical staging (TAH + BSO ± LN dissection) + adjuvant RT/chemo based on risk stratification. Molecular classification (POLE, MSI, p53) increasingly important.

HRT Rules: Presence of uterus → cannot use unopposed oestrogen ^[5]. Time since menopause > 2 years → continuous combined regimen ^[5]. Breakthrough bleeding in first 6 months → no immediate intervention; after that → endometrial biopsy if abnormal pattern ^[5]. Principle = lowest dose for shortest possible duration ^[5].

Fibroids: Post-menopausal growth is worrisome of malignancy ^[8] → surgical excision. GnRH agonists for pre-operative size reduction only — NOT for long-term use ^[8].

Active Recall - PMB: Management

References

^[1] Lecture slides: Adrian Lui Gynecology Notes.pdf (p22) ^[5] Lecture slides: Adrian Lui Gynecology Notes.pdf (p36) ^[7] Senior notes: Maksim Surgery Notes.pdf (p186) ^[8] Lecture slides: Adrian Lui Gynecology Notes.pdf (p92) ^[9] Senior notes: Ryan Ho Diagnostic Radiology.pdf (p85)

Complications of Post-Menopausal Bleeding (PMB) and Its Underlying Causes

Complications in PMB fall into three broad categories:

Complications of the underlying cause itself (i.e., what happens if the pathology goes untreated)
Complications of the diagnostic investigations
Complications of the treatments

Understanding each from first principles helps you anticipate, prevent, and manage them.

1. Complications of the Underlying Causes (Untreated)

Complication	Mechanism	Clinical Consequence
Iron deficiency anaemia	Chronic blood loss → depletion of iron stores → inadequate haemoglobin synthesis	Fatigue, pallor, dyspnoea, tachycardia, exacerbation of cardiovascular disease in elderly. Even "spotting" can cause significant anaemia if persistent over months.
Anxiety and psychological distress	PMB is a "cancer scare" — patients fear malignancy. Recurrent bleeding causes uncertainty and distress.	Impact on quality of life, sleep, relationships. Important to address with empathetic counselling during workup.
Delayed diagnosis of malignancy	If PMB is dismissed as "just atrophy" without proper investigation, an underlying cancer may be missed.	Progression from early-stage (curable) to advanced-stage (incurable) disease. This is the single most important complication to prevent — and why endometrial aspirate is mandatory in ALL cases of PMB ^[1].

The Danger of Normalising PMB

The biggest complication of PMB is failure to investigate. Because ~90% of cases are benign, there is a temptation (by patients and clinicians alike) to attribute all PMB to atrophy. But PMB is a worrisome symptom → must rule out CA endometrium ^[1]. A 10% cancer rate means 1 in 10 women with PMB has malignancy. Never normalise PMB without completing the workup.

Complication	Mechanism
Recurrent vaginal bleeding	Persistent thin, fragile epithelium → repeated microtrauma → recurrent spotting
Secondary vaginal infections	Loss of Lactobacillus (due to ↓ glycogen) → ↑ vaginal pH → colonisation by pathogenic bacteria (e.g., Streptococcus, E. coli, anaerobes) → vaginitis with offensive discharge
Dyspareunia → sexual dysfunction	Thin, dry vaginal epithelium with ↓ elasticity and ↓ lubrication → pain during intercourse → avoidance of intimacy → relationship strain
Urinary complications	Atrophic bladder epithelium → urgency, urge incontinence, frequency, dysuria, UTI, voiding difficulties ^[1]. The urethral and trigone epithelium shares the same embryological origin (urogenital sinus) as the vaginal epithelium and is equally oestrogen-dependent.
Vaginal stenosis	Chronic atrophy and inflammation → adhesions and narrowing of the vaginal canal → difficulty with speculum examination and intercourse
Cervical stenosis	Atrophy of the cervical canal → fibrosis → stenosis → haematometra or pyometra (especially in elderly women)

Haematometra and Pyometra — Important Complications of Cervical Stenosis

Haematometra = Greek: haima (blood) + metra (womb) — blood trapped in the uterine cavity. Pyometra = Greek: pyo (pus) + metra (womb) — infected fluid/pus trapped in the uterine cavity.

Pathophysiology: Post-menopausal cervical stenosis (from atrophy, scarring, or tumour) → obstruction of drainage from the uterine cavity → accumulation of blood (haematometra) or infected secretions (pyometra).

Why is this dangerous?

Pyometra can cause sepsis in elderly, frail patients.
A distended, thinned uterine wall may perforate (spontaneously or during instrumentation).
Must always exclude endometrial cancer as the cause of the obstruction — cancer can cause both cervical stenosis and endometrial bleeding/secretions.

Clinical features: Lower abdominal pain, distended tender uterus on bimanual examination, fever (if infected), purulent or blood-stained discharge if partial obstruction.

Management: Cervical dilatation and drainage + endometrial sampling (to exclude malignancy) + antibiotics (if pyometra).

Complication	Mechanism	Risk
Progression to endometrial cancer	Continued unopposed oestrogen → accumulation of genetic mutations → hyperplasia-carcinoma sequence	Without atypia: ~1–3%. With atypia: ~29% (and ~40% already harbour concurrent carcinoma)
Heavy menorrhagia / anaemia	Thickened, fragile, disorganised endometrium with abnormal vasculature → irregular, heavy shedding	May require iron supplementation or transfusion
Recurrence after treatment	If the underlying cause of unopposed oestrogen is not addressed (e.g., ongoing obesity, persistent HRT without progestin), hyperplasia will recur	Lifelong surveillance may be needed

Complication	Mechanism
Local invasion	Tumour invades myometrium → serosa → adjacent structures (bladder, rectum, parametria) → pain, haematuria, rectal bleeding, fistulae
Lymphatic spread	Pelvic → para-aortic lymph nodes → lymphoedema of lower limbs, lymphatic obstruction
Haematogenous metastasis	Lung (most common distant site), liver, bone, brain → organ-specific symptoms
Peritoneal carcinomatosis	Especially Type II (serous) histology → seeding across peritoneal surfaces → ascites, bowel obstruction
Vaginal vault recurrence	After hysterectomy, tumour may recur at the vaginal cuff → vaginal bleeding post-treatment
Ureteric obstruction	Tumour mass or lymphadenopathy compresses ureters → hydronephrosis → renal failure

2. Complications of Diagnostic Investigations

Complication	Mechanism	Frequency
Pain / cramping	Cervical instrumentation + uterine distension; prostaglandin release from endometrial disruption	Common (~50%) — usually mild and self-limiting
Vasovagal syncope	Cervical manipulation triggers vagal reflex → bradycardia + hypotension	Uncommon (~1–2%)
Uterine perforation	Instrument passes through the thin post-menopausal uterine wall (atrophic myometrium is thin)	Rare (< 1%)
Infection (endometritis)	Introduction of vaginal flora into sterile uterine cavity	Rare (< 1%)
Inadequate sample	Endometrium too thin to sample (post-menopausal atrophy), cervical stenosis preventing access	~10–20% of EA in post-menopausal women
False negative	Blind sampling misses focal lesion (polyp, small cancer)	~5–10% — addressed by adding hysteroscopy

Complication	Mechanism	Frequency
Uterine perforation	Instrument perforates the myometrium — risk is higher in post-menopausal women (thin, atrophic uterine wall) and in women with cervical stenosis (forcing the scope)	~0.1–1%
Haemorrhage	Injury to myometrial vessels during biopsy or polypectomy; endometrial surface bleeding	< 1% (significant haemorrhage)
Infection	Ascending infection from instrumentation	< 1%
Fluid overload	Excessive absorption of distension medium (saline or glycine) through open venous sinuses in the endometrium → dilutional hyponatraemia (especially with hypotonic media like glycine)	Rare with saline (isotonic); more relevant with glycine in operative hysteroscopy
Cervical trauma / false passage	Forced dilatation of stenotic cervix → cervical laceration or creation of a false channel	Uncommon
Air / gas embolism	CO₂ distension medium or air trapped during procedure → enters venous circulation	Extremely rare; potentially fatal

Uterine Perforation — What To Do

If perforation is suspected during hysteroscopy (instrument advances further than expected, sudden loss of distension pressure, patient reports sudden sharp pain):

Stop the procedure immediately
Assess haemodynamic stability
If stable: observe with serial vitals, haemoglobin, abdominal examination. Most perforations (especially with blunt instruments like the Pipelle or hysteroscope tip) are small and seal spontaneously.
If unstable or bowel/bladder injury suspected: laparoscopy or laparotomy to assess and repair. The risk of perforation is higher in post-menopausal women because the myometrium is atrophic and thin.

3. Complications of Treatments

Complication	Mechanism
Local irritation / burning	Cream base may irritate the atrophic, inflamed epithelium; usually transient
Vaginal discharge	Cream vehicle causes increased discharge — cosmetically bothersome but harmless
Breast tenderness	Minimal systemic absorption of oestrogen → mild breast stimulation. Uncommon at standard doses
Endometrial stimulation	At very high doses or prolonged use, some systemic absorption may stimulate the endometrium → breakthrough bleeding. At recommended doses (e.g., Premarin 0.5g vaginal cream), this is negligible and does NOT require concurrent progestin
Patient non-compliance	Application is messy; some women find vaginal cream insertion uncomfortable or culturally unacceptable → treatment failure

Complication	Mechanism
Irregular bleeding / spotting	Progestin-induced endometrial changes — initially may worsen before improving
Weight gain	Fluid retention + appetite stimulation (especially with MPA and megestrol at high doses)
Mood changes / depression	Progesterone modulates GABA-A receptors and serotonin pathways → mood alterations
Bloating / GI upset	Smooth muscle relaxation → ↓ GI motility
Mirena LNG-IUS specific	Expulsion (~5%), perforation at insertion (rare), infection (rare), ectopic hormone effects (acne, breast tenderness)
Treatment failure	~10–30% do not respond to progestin → progression to atypical hyperplasia or carcinoma → require hysterectomy

General complications of hysterectomy (applicable to TAH, laparoscopic, or vaginal approach):

Category	Complication	Mechanism
Immediate	Haemorrhage	Injury to uterine, ovarian, or iliac vessels during surgery
	Anaesthetic complications	General anaesthesia risks (aspiration, anaphylaxis, cardiac events — especially in elderly post-menopausal women with comorbidities)
Early	Wound complications: infection, pain, bruises, delayed healing, keloid formation ^[10]	Surgical trauma + bacterial contamination
	Bladder injury	Bladder is anatomically anterior to the uterus and cervix; risk of injury during dissection, especially in radical hysterectomy
	Ureteric injury	Ureter crosses under the uterine artery ("water under the bridge") — risk during ligation of uterine artery
	Bowel injury	Adhesions from prior surgery/endometriosis, distorted anatomy from large tumour
	VTE (DVT / PE)	Pelvic surgery → venous stasis (immobility) + endothelial damage + hypercoagulability (post-operative state). Post-menopausal women are at increased baseline VTE risk. Death in 6 weeks mainly due to PE or MI ^[10]
	Infection (pelvic abscess, vault cellulitis)	Contamination from vaginal flora ascending to the surgical field
Late	Vault prolapse	Removal of the cervix weakens the apical support of the vaginal vault → descent over months to years
	Vaginal vault granulation tissue	Granulation tissue at the sutured vault → contact bleeding (may be confused with recurrent PMB)
	Lymphoedema	Lymphadenectomy-related: lymphocyst (< 10%–20%), lymphoedema (< 20%), lymphangitis ^[10]
	Adhesion-related complications	Post-surgical adhesions → bowel obstruction, chronic pelvic pain
	Psychological impact	Loss of the uterus → grief, altered body image, especially if the procedure was unexpected. Less relevant in post-menopausal women but still important to address.
	Premature menopause	If BSO performed in premenopausal women (not relevant in PMB as already post-menopausal)

Adjuvant chemoradiation regimen: standard field pelvic irradiation + cisplatin 40 mg/m² weekly during external radiotherapy ^[10].

Complication	Mechanism	Timing
Radiation cystitis	Radiation damages the bladder urothelium → inflammation → haematuria, frequency, urgency	Acute (during/shortly after RT) or late (months–years)
Radiation proctitis	Radiation damages rectal mucosa → inflammation → diarrhoea, rectal bleeding, tenesmus	Acute or late
Vaginal stenosis	Radiation-induced fibrosis of the vaginal vault → narrowing and shortening → dyspareunia, difficulty with vault examination	Late (months–years). Prevented by vaginal dilator use post-RT
Lymphoedema	Combined effect of lymph node dissection + radiation → lymphatic obstruction → chronic lower limb swelling	Late (can be progressive and irreversible)
Radiation enteritis	Small bowel loops in the radiation field → mucosal damage → malabsorption, diarrhoea, strictures, fistulae	Late
Secondary malignancy	Radiation-induced DNA damage to normal tissues → second cancers (bladder, rectal, sarcoma)	Very late (years–decades)
Bone marrow suppression	Pelvic bone marrow in radiation field → ↓ haematopoiesis → pancytopaenia (especially if concurrent chemotherapy with cisplatin)	Acute
Renal toxicity	Cisplatin is nephrotoxic (direct tubular injury)	Acute — requires aggressive hydration during administration

Tamoxifen side effects: weight gain, flushing, ↑ risk of CA corpus, VTE ^[7].

Complication	Mechanism
Endometrial cancer	Tamoxifen is a partial oestrogen agonist in the endometrium → endometrial proliferation → polyps, hyperplasia, carcinoma (2× risk in post-menopausal women) ^[2]
Endometrial polyps	Same mechanism — oestrogen-agonist stimulation of focal endometrial overgrowth
VTE (DVT / PE)	Oestrogen-agonist effect on hepatic clotting factor synthesis → prothrombotic state
Vasomotor symptoms (hot flushes)	Oestrogen antagonism in the hypothalamic thermoregulatory centre → dysregulation of temperature set-point
Cataracts	Tamoxifen accumulates in ocular tissues → lens opacification (rare but established)
Uterine sarcoma	Rare — but tamoxifen is associated with a small increase in risk of uterine sarcoma

These are not complications of PMB per se, but complications of the hypoestrogenic post-menopausal state that coexists with PMB and informs management decisions:

Complication	Mechanism	Relevance to PMB
Cardiovascular disease	Oestrogen is protective to vasculature + favourable effect on lipid profile → ↑ chance of atherosclerosis in menopause ^[1]	Informs HRT decision-making — HRT addresses vasomotor symptoms but is NOT primarily for cardiovascular protection
Postmenopausal osteoporosis	Oestrogen has antiparathyroid and anticatabolic effects in bones → exaggerated bone loss after menopause ^[1]	May influence choice of SERM vs HRT vs bisphosphonate in the broader management of the post-menopausal woman
Genitourinary syndrome of menopause	Atrophic bladder epithelium → urgency, urge incontinence, frequency, dysuria, UTI, voiding difficulties. ↓ collagen → soft tissue laxity, ↓ muscle strength ^[1]	These symptoms often coexist with atrophic vaginitis and improve with local oestrogen therapy — reinforcing the importance of treating the underlying oestrogen deficiency

References

^[1] Lecture slides: Adrian Lui Gynecology Notes.pdf (p22, p12) ^[2] Lecture slides: Adrian Lui Gynecology Notes.pdf (p96) ^[7] Senior notes: Maksim Surgery Notes.pdf (p186) ^[10] Lecture slides: Adrian Lui Gynecology Notes.pdf (p123) ^[11] Lecture slides: Adrian Lui Gynecology Notes.pdf (p90)

High Yield Summary

Definition: Any uterine bleeding > 1 year after last natural menstrual period. Menopause = 12 months amenorrhoea (clinical, retrospective diagnosis).

Epidemiology: 4–11% of postmenopausal women; ~10% due to malignancy — most commonly endometrial carcinoma.

Most common cause: Atrophic vaginitis/endometritis (hypoestrogenic) — pale, dry, shiny vaginal epithelium with petechiae, loss of rugae.

Most important to exclude: Endometrial cancer.

Unopposed oestrogen drives hyperplasia → carcinoma. RFs: obesity (peripheral aromatisation), PCOS/anovulation, unopposed oestrogen HRT (2–10×), tamoxifen (2×), nulliparity, Lynch syndrome, DM.

Combined oestrogen-progestin HRT does NOT increase endometrial cancer risk — progesterone protects.

Type I endometrial CA (endometrioid, ~80%): oestrogen-driven, hyperplasia precursor, better prognosis. Type II (serous/clear cell): not oestrogen-driven, worse prognosis.

Tamoxifen: Partial agonist in endometrium. Asymptomatic → no routine surveillance. Symptomatic → EA + diagnostic hysteroscopy within 2 weeks. TVUS unreliable (myometrial vacuolation).

Always confirm source — exclude haematuria, rectal bleeding. History must include TCM, supplements, HRT, tamoxifen.

High Yield Summary — Differential Diagnosis

PMB is a worrisome symptom → must rule out CA endometrium. Atrophic vaginitis is a diagnosis of exclusion.

Rank	Cause	Frequency
1	Endometrial/cervical polyps	~37.7% (hysteroscopic series)
2	Atrophic vaginitis/endometritis	~30.8% (commonest clinical cause)
3	Proliferative/secretory endometrium (oestrogen exposure)	~14.5%
4	Malignancy	~6.6–10%
5	Fibroids	~6.2%

Two pathophysiological drivers: (1) Hypoestrogenic (atrophy — most common) vs (2) Hyperestrogenic (hyperplasia, polyps, CA).

Source	Key DDx
Endometrial	Atrophy, polyp, hyperplasia, endometrial CA, sarcoma
Cervical	Polyp, ectropion, cervicitis, cervical CA
Vaginal/vulval	Atrophic vaginitis, trauma, vaginal/vulval CA
Non-gynaecological	Urethral caruncle, bladder CA, rectal bleeding

Cervical CA vs endometrial CA: PCB + visible cervical lesion → biopsy directly. Spontaneous PMB + blood at os + normal cervix → endometrial source.

Visible cervical lesion → cervical biopsy directly — NOT smear alone (can miss invasive CA).

High Yield Summary — Diagnosis

Mandatory in ALL PMB:

Cervical cytology if no regular screening
Endometrial aspirate (EA) — mandatory
TVUS for endometrial thickness

ET on TVUS	Action
≤ 4 mm	NPV 99.4–100% for endometrial CA — reassuring if EA benign
> 4 mm	Hysteroscopy ± directed biopsy
Incidental asymptomatic ET > 11 mm	EA only if other US findings or RFs (NOT routine at 8 mm)

Hysteroscopy indicated if: on tamoxifen, ET > 4 mm, recurrent/refractory symptoms despite atrophic treatment.

EA histology: Atrophic/inactive (reassuring) | Hyperplasia without atypia (progestogen) | Atypical (hysterectomy) | Carcinoma (staging).

Discordant result (thick ET + benign/inadequate EA) → hysteroscopy essential (EA is blind, misses focal lesions).

HRT bleeding: First 6 months → observe. Cyclical: bleeding not at progestogen withdrawal → biopsy. Continuous combined: bleeding after amenorrhoea → endometrial biopsy.

Algorithm: History + exam → EA + TVUS → hysteroscopy if indicated → treat by histology.

High Yield Summary — Management

Treat the underlying cause.

Diagnosis	Management
Atrophic vaginitis	Local oestrogen — Premarin cream 0.5g QD × 2 weeks then 3×/week × 6 months. No progestogen needed (minimal systemic absorption). Refractory → hysteroscopy
Endometrial polyp	Hysteroscopic polypectomy + histology (0.5–3% malignant potential)
Hyperplasia without atypia	Progestogen (Mirena preferred, ~96% regression) + repeat EA 3–6 months
Atypical hyperplasia	Hysterectomy (TAH + BSO); ~29% progression, ~40% concurrent CA. Fertility-sparing: high-dose progestogen + surveillance
Endometrial cancer	TAH + BSO ± LN dissection + adjuvant RT/chemo by stage
Cervical cancer	Stage-dependent (surgery or CCRT)
Exogenous oestrogen	Stop source; add progestogen if uterus intact on unopposed HRT

HRT rules: Uterus present → cannot use unopposed oestrogen. > 2 years post-menopause → continuous combined (aim amenorrhoea). < 2 years → cyclical. Principle: lowest dose, shortest duration.

Postmenopausal fibroid growth → worrisome of sarcoma → surgical excision.

Follow-up: Review histology; reassess atrophic treatment at 3–6 months; oncology follow-up for malignancy.

High Yield Summary — Complications

Most important complication to prevent: Delayed diagnosis of endometrial cancer — EA mandatory in all PMB.

Atrophic complications: Recurrent bleeding, secondary infections, dyspareunia, urinary symptoms (urgency, frequency, UTI), vaginal stenosis, cervical stenosis → haematometra/pyometra (must exclude CA as cause of obstruction).

Hyperplasia progression: Without atypia ~1–3%; atypical ~29% (40% concurrent CA at hysterectomy).

Endometrial CA: Local invasion, lymphatic spread, ureteric obstruction → hydronephrosis → renal failure.

Cervical CA complications: Parametrial invasion, ureteric obstruction, bladder/rectal fistulae, lymphoedema.

Investigation complications: EA — pain, inadequate sample (~10–20%), perforation (< 1%). Hysteroscopy — perforation higher in atrophic uterus, fluid overload.

Treatment complications: Local oestrogen — minimal systemic effects. Progestogens — irregular bleeding, treatment failure (~10–30%). Hysterectomy — haemorrhage, ureteric/bladder injury, VTE, vault prolapse. RT — cystitis, proctitis, vaginal stenosis, secondary malignancy. Tamoxifen — endometrial CA, VTE, polyps.

Broader postmenopausal state: ↑CVD (loss of oestrogen vasculoprotection), osteoporosis (↑RANKL:OPG).

Post-menopausal Bleeding (pmb)

Post-Menopausal Bleeding (PMB)

3. Risk Factors

4. Anatomy and Function (Relevant to PMB)

Hormonal Regulation of the Endometrium

5. Aetiology and Pathophysiology

5.2 Detailed Pathophysiology of Each Cause

7. Clinical Features

7.2 Signs

7.3 Signs Specific to Particular Aetiologies

8. Long-Term Sequelae of the Post-Menopausal State (Context for PMB)

9. Evaluation (History and Physical Examination Approach)

Active Recall - Post-Menopausal Bleeding (PMB): Definition, Epidemiology, Aetiology, and Clinical Features

Differential Diagnosis of Post-Menopausal Bleeding (PMB)

Detailed Differential Diagnoses

Active Recall - Differential Diagnosis of PMB

References

Diagnostic Criteria, Algorithm, and Investigation Modalities for Post-Menopausal Bleeding (PMB)

1. Diagnostic Criteria

2. Diagnostic Algorithm

3. Investigation Modalities — Detailed

Active Recall - PMB: Diagnostic Criteria, Algorithm, and Investigations

References

Management of Post-Menopausal Bleeding (PMB)

Detailed Management by Aetiology

3. Endometrial Hyperplasia

Active Recall - PMB: Management

References

Complications of Post-Menopausal Bleeding (PMB) and Its Underlying Causes

1. Complications of the Underlying Causes (Untreated)

Haematometra and Pyometra — Important Complications of Cervical Stenosis

2. Complications of Diagnostic Investigations

3. Complications of Treatments

Active Recall - PMB: Complications

References

On this page

Post-menopausal Bleeding (pmb)

1. Definition

2. Epidemiology

3. Risk Factors

3.1 Risk Factors for Endometrial Cancer (the key concern in PMB)

3.2 Risk Factors for Atrophic Changes (the most common cause)

4. Anatomy and Function (Relevant to PMB)

4.1 The Endometrium

4.2 The Vaginal Epithelium

4.3 The Cervix

4.4 Blood Supply

5. Aetiology and Pathophysiology

5.1 Overview of Causes

5.2 Detailed Pathophysiology of Each Cause

A. Atrophic Vaginitis / Atrophic Endometritis (Most Common)

B. Endometrial Cancer

C. Endometrial Hyperplasia

D. Endometrial Polyps

E. Oestrogen Exposure

F. Cervical Causes

G. Vaginal and Vulval Causes

6. Classification

7. Clinical Features

7.1 Symptoms

7.2 Signs

A. General Examination

B. Speculum Examination

C. Bimanual Examination

7.3 Signs Specific to Particular Aetiologies

Atrophic Vaginitis

Endometrial Cancer

Cervical Cancer

7.4 Red Flags in PMB

8. Long-Term Sequelae of the Post-Menopausal State (Context for PMB)

8.1 Cardiovascular Disease

8.2 Postmenopausal Osteoporosis

9. Evaluation (History and Physical Examination Approach)

9.1 History

9.2 Physical Examination

Active Recall - Post-Menopausal Bleeding (PMB): Definition, Epidemiology, Aetiology, and Clinical Features

References

Conceptual Framework

Differential Diagnoses by Frequency

Detailed Differential Diagnoses

1. Atrophic Vaginitis / Atrophic Endometritis — Commonest [1]

2. Endometrial Polyps — ~37.7% [3]

3. Endometrial Cancer — ~6.6–10% [1][3]

4. Cervical Cancer [3]

5. Endometrial Hyperplasia [1]

6. Uterine Fibroids (Leiomyomata) — ~6.2% [3]

7. Uterine Sarcoma [1]

8. Oestrogen Exposure [1]

9. Vaginal / Vulval Causes [1]

10. Non-Gynaecological Causes

Diagnostic Approach by Anatomy (Mermaid Diagram)

Investigation-Guided Differential Diagnosis

Key Distinguishing Clinical Features

Approach to Narrowing the Differential

Active Recall - Differential Diagnosis of PMB

1. Diagnostic Criteria

1.1 Confirming Menopause

1.2 Key Diagnostic Thresholds

2. Diagnostic Algorithm

2.1 Step-by-Step Approach

2.2 Algorithm (Mermaid Diagram)

2.3 Special Algorithm: Patients on Tamoxifen

2.4 Special Considerations: HRT and Breakthrough Bleeding

3. Investigation Modalities — Detailed

3.1 Cervical Cytology (Pap Smear / Liquid-Based Cytology)

3.2 Endometrial Aspirate (EA) / Pipelle Biopsy

3.3 Transvaginal Ultrasound (TVUS)

3.4 Hysteroscopy ± Endometrial Biopsy

3.5 Dilatation and Curettage (D&C)

3.6 Additional Investigations

3.7 Summary Table: Matching Investigation to Clinical Scenario

4. Interpreting Combined Investigation Results

Active Recall - PMB: Diagnostic Criteria, Algorithm, and Investigations

Core Principle

Management Algorithm

Detailed Management by Aetiology